CTEV Quote, Financials, Valuation and Earnings

GoodRx Holdings, Inc. has a net margin of -28.36% compared to Claritev Corp.'s net margin of 0.57%. Claritev Corp.'s return on equity of -1037.49% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

Claritev Corp. has a consensus price target of $85.00, signalling upside risk potential of 150.37%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $5.09 which suggests that it could grow by 87.8%. Given that Claritev Corp. has higher upside potential than GoodRx Holdings, Inc., analysts believe Claritev Corp. is more attractive than GoodRx Holdings, Inc..

Claritev Corp. has a beta of 0.518, which suggesting that the stock is 48.247% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

Claritev Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Claritev Corp. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

Claritev Corp. quarterly revenues are $246M, which are larger than GoodRx Holdings, Inc. quarterly revenues of $196M. Claritev Corp.'s net income of -$69.8M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Claritev Corp.'s price-to-earnings ratio is -- while GoodRx Holdings, Inc.'s PE ratio is 31.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Claritev Corp. is 0.58x versus 1.24x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -28.36% compared to Claritev Corp.'s net margin of 11.54%. Claritev Corp.'s return on equity of -1037.49% beat National Research Corp.'s return on equity of 61.55%.

Claritev Corp. has a consensus price target of $85.00, signalling upside risk potential of 150.37%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Claritev Corp. has higher upside potential than National Research Corp., analysts believe Claritev Corp. is more attractive than National Research Corp..

Claritev Corp. has a beta of 0.518, which suggesting that the stock is 48.247% less volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Claritev Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 3.03% to investors and pays a quarterly dividend of $0.12 per share. Claritev Corp. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Claritev Corp. quarterly revenues are $246M, which are larger than National Research Corp. quarterly revenues of $34.6M. Claritev Corp.'s net income of -$69.8M is lower than National Research Corp.'s net income of $4M. Notably, Claritev Corp.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 22.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Claritev Corp. is 0.58x versus 2.60x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of -28.36% compared to Claritev Corp.'s net margin of -2156852.78%. Claritev Corp.'s return on equity of -1037.49% beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

Claritev Corp. has a consensus price target of $85.00, signalling upside risk potential of 150.37%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 956.34%. Given that Predictive Oncology, Inc. has higher upside potential than Claritev Corp., analysts believe Predictive Oncology, Inc. is more attractive than Claritev Corp..

Claritev Corp. has a beta of 0.518, which suggesting that the stock is 48.247% less volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

Claritev Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Claritev Corp. pays -- of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

Claritev Corp. quarterly revenues are $246M, which are larger than Predictive Oncology, Inc. quarterly revenues of $3.6K. Claritev Corp.'s net income of -$69.8M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, Claritev Corp.'s price-to-earnings ratio is -- while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Claritev Corp. is 0.58x versus 13.06x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -28.36% compared to Claritev Corp.'s net margin of 9.46%. Claritev Corp.'s return on equity of -1037.49% beat Spok Holdings, Inc.'s return on equity of 10.88%.

Claritev Corp. has a consensus price target of $85.00, signalling upside risk potential of 150.37%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.29%. Given that Claritev Corp. has higher upside potential than Spok Holdings, Inc., analysts believe Claritev Corp. is more attractive than Spok Holdings, Inc..

Claritev Corp. has a beta of 0.518, which suggesting that the stock is 48.247% less volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

Claritev Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.6% to investors and pays a quarterly dividend of $0.31 per share. Claritev Corp. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

Claritev Corp. quarterly revenues are $246M, which are larger than Spok Holdings, Inc. quarterly revenues of $33.9M. Claritev Corp.'s net income of -$69.8M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, Claritev Corp.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Claritev Corp. is 0.58x versus 1.93x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.